Akihiro Nishiyama

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 363 citations · Full text

Medicine, Oncology, Pharmacology +17

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Shunli Peng, Rong Wang, Xiaojuan Zhang et al. · Molecular Cancer · 2019 · 320 citations · Full text

Medicine, Oncology, Pharmacology +17

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka et al. · Cancer · 2013 · 178 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka et al. · Journal of Thoracic Oncology · 2015 · 156 citations · Full text

Medicine, Genetics, Oncology +16

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Naoko Okura, Naoya Nishioka, Tadaaki Yamada et al. · Clinical Cancer Research · 2020 · 113 citations

Medicine, Oncology, Pharmacology +17